Two acclaimed subject matter experts from Worldwide Clinical Trials, a global contract research organization (CRO), will share their exclusive insights into the latest advancements in rapidly evolving GLP-1 research at the 2nd Annual GLP-1-Based Therapeutics Summit in Boston.
On Wednesday, 30 April, at 2:30 p.m. ET, the authoritative session, “Future of GLP-1 Trials: Innovation and Perspectives,” will be presented by Worldwide’s Alessandra Vignola, President of Cardiovascular and Metabolic, and Natalia Castro, Executive Director of Cardiovascular and Metabolic. Their fresh viewpoints on GLP-1 clinical trials targeting obesity, weight loss, diabetes, and more will explore:
“This session offers a unique opportunity to examine how innovative trial designs and advanced technologies are shaping the future of GLP-1 therapies,” explained Vignola, who has deep therapeutic expertise after more than 30 years of experience in pharmaceutical and clinical research. As leader of Worldwide’s cardiometabolic program, she enjoys using her knowledge to give operational and strategic guidance to others.
“We look forward to driving meaningful conversations at the GLP-1-Based Therapeutics Summit,” agreed Castro, whose 20 years of seasoned leadership includes her current work as Worldwide’s Metabolic Franchise Area Lead. “We hope that by contributing to this premier gathering of those at the forefront of GLP-1 research, we will help not only transform clinical research but also make a profound difference in the lives of patients across the globe.”
To learn more about the session and reserve your spot, visit the Worldwide's events page.
About Worldwide Clinical Trials:
Worldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare disease, and cardiometabolic and inflammatory disease. Its global footprint spans over 60 countries with more than 3,500 team members. For more information, visit www.worldwide.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250429996698/en/